Hiroyuki Yasuda

Dr. Hiroyuki Yasuda


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
HYHiroyuki Yasuda
Hiroyuki Yasuda
SKSusumu Kobayashi
Susumu Kobayashi
DCDaniel Costa
Daniel Costa

18 December 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HYHiroyuki Yasuda
Hiroyuki Yasuda
EPEunyoung Park
Eunyoung Park
CYCai-Hong Yun
Cai-Hong Yun
NSNatasha J. Sng
Natasha J. Sng
ALAntonio R. Lucena-Araujo
Antonio R. Lucena-Araujo
DCDaniel Costa
Daniel Costa
Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19 deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine kinase inhibitors (TKIs) in advanced non–small cell lung cancer (NSCLC). However, EGFR exon 20 insertion mutations (~10% of all EGFR mutations) are generally associated with insensitivity to available TKIs (gefitinib, erlotinib, and afatinib). The basis of this primary resistance is poorly understood. We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. The crystal structure of a representative TKI-insensitive mutant (D770_N771insNPG) reveals an unaltered adenosine triphosphate–binding pocket, and the inserted residues form a wedge at the end of the C helix that promotes the active kinase conformation. Unlike EGFR-L858R, D770_N771insNPG activates EGFR without increasing its affinity for EGFR TKIs. Unexpectedly, we find that EGFR-A763_Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. Analysis of the A763_Y764insFQEA mutant indicates that the inserted residues shift the register of the C helix in the N-terminal direction, altering the structure in the region that is also affected by the TKI-sensitive EGFR-L858R. Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs.

1 November 2020 in Cell
Verified
Journal Article
Closed access
KKKenta Kawasaki
Kenta Kawasaki
KTKohta Toshimitsu
Kohta Toshimitsu
MMMami Matano
Mami Matano
MFMasashi Fujita
Masashi Fujita
MFMasayuki Fujii
Masayuki Fujii
TSToshiro Sato
Toshiro Sato

17 July 2013 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
HTHideki Terai
Hideki Terai
KSKenzo Soejima
Kenzo Soejima
HYHiroyuki Yasuda
Hiroyuki Yasuda
SNSohei Nakayama
Sohei Nakayama
JHJunko Hamamoto
Junko Hamamoto
TBTomoko Betsuyaku
Tomoko Betsuyaku
Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidation of the mechanism of acquired resistance to EGFR-TKIs is of great importance. In this study, gefitinib-resistant cell line models were established by long-term exposure to gefitinib using the gefitinib-sensitive lung cancer cell lines, PC9 and HCC827. Expression analyses indicated that both FGFR1 and FGF2 were increased in PC9 gefitinib-resistant (PC9 GR) cells as compared with PC9 naïve (PC9 na) cells. Importantly, proliferation of gefitinib-resistant cells was dependent on the FGF2 -FGFR1 pathway. Mechanistically, inhibition of either FGF2 or FGFR1 by siRNA or FGFR inhibitor (PD173074) restored gefitinib sensitivity in PC9 GR cells. These data suggest that FGF2 -FGFR1 activation through an autocrine loop is a novel mechanism of acquired resistance to EGFR-TKIs. Mol Cancer Res; 11(7); 759–67. ©2013 AACR.

13 April 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
SNShigenari Nukaga
Shigenari Nukaga
HYHiroyuki Yasuda
Hiroyuki Yasuda
KTKatsuya Tsuchihara
Katsuya Tsuchihara
JHJunko Hamamoto
Junko Hamamoto
KMKeita Masuzawa
Keita Masuzawa
KSKenzo Soejima
Kenzo Soejima
EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation-selective inhibitors with minimal effects on wild-type EGFR. Acquired resistance develops to these agents, however, the mechanisms are as yet uncharacterized. In this study, we report that the Src–AKT pathway contributes to acquired resistance to these TKI. In addition, amplification of EGFR wild-type alleles but not mutant alleles was sufficient to confer acquired resistance. These findings underscore the importance of signals from wild-type EGFR alleles in acquiring resistance to mutant-selective EGFR-TKI. Our data provide evidence of wild-type allele-mediated resistance, a novel concept of acquired resistance in response to mutation-selective inhibitor therapy in cancer treatment. Cancer Res; 77(8); 2078–89. ©2017 AACR.

15 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
THToshiyuki Hirano
Toshiyuki Hirano
HYHiroyuki Yasuda
Hiroyuki Yasuda
TTTetsuo Tani
Tetsuo Tani
JHJunko Hamamoto
Junko Hamamoto
AOAyano Oashi
Ayano Oashi
KSKenzo Soejima
Kenzo Soejima
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer